CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：Therapeutic progress in relapsed/refractory multiple myeloma.
Therapeutic progress in relapsed/refractory multiple myeloma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
多发性骨髓瘤（MM）的治疗在过去20年中由于新药和新技术的应用而不断发展。MM的标准一线治疗由基于免疫调节药物和蛋白酶体抑制剂的三药诱导方案联合自体干细胞移植组成。然而，MM仍然无法治愈；因此，复发/难治性MM（RRMM）的治疗方法正在迅速涌现和演变。本研究旨在总结和回顾过去5年RRMM试验的结果，为相关领域的从业者提供整体概览和见解，并为临床试验研究者提供更多思路。本研究表明，daratumumab和isatuximab作为治疗选择继续取得显著进展。此外，新型抗体药物，如elotuzumab和selinexor，以及双特异性抗体teclistamab和talquetamab，目前正在进行临床研究，结果令人鼓舞。然而，靶向B细胞成熟抗原的CAR-T 细胞疗法仍然是MM治疗的最佳方法。
Improvement in the therapeutics for multiple myeloma (MM) has been continuously developed owing to the application of novel drugs and technologies in the last 20 years. The standard first-line therapy for MM consists of a three-drug induction regimen based on immunomodulatory drugs and proteasome inhibitors combined with autologous stem cell transplantation.
However, MM remains incurable; therefore, therapies for relapsed/refractory MM (RRMM) are emerging and evolving rapidly.
This study aimed to summarize and review the results of RRMM trials over the past 5 years to provide a holistic overview and insights for practitioners in related fields and to provide additional ideas for clinical trialists.
This study shows that daratumumab and isatuximab continue to significantly advance as treatment options.
Additionally, novel antibody drugs, such as elotuzumab and selinexor, as well as bispecific antibodies, teclistamab and talquetamab, are currently undergoing clinical research with promising outcomes.
However, chimeric antigen receptor-T cell therapy targeting B-cell maturation antigen remains the optimal approach for MM treatment.
MEMBER ACCOUNT
登录成功会直接打开下一页。
